Table 3. Main characteristics of studies that evaluated the relationships of PIK3CA mutations and the OS/RFS in HR+ breast cancer patients.
| First author | Year of publication | Country | Design | Treatment | No.of PIK3CA mutant patients (%) | Sequenced PIK3CA | Mutation analysis methods | Median follow-up time (months, range) | Outcome type |
|---|---|---|---|---|---|---|---|---|---|
| Bozhanov SS | 2010 | Bulgaria | HB | H, C, RT | 24(30.0) | exon 9 and 20 | DS | 69 (11–96) | OS |
| Cuorvo LV | 2014 | Italy | HB | H, C, T | 50(20.3) | exon 9 and 20 | HRM + PA | 97 (8–140) | OS* |
| Li SY | 2006 | Australia | HB | H, C | 69(41.1) | exon 7, 9 and 20 | F-SSCP | 50 (2–78) | OS |
| Sanchez CG | 2011 | USA | HB | NR | 13(48.1) | exon 9 and 20 (HS) | DS | 51.7 (0.9–256.7) | OS |
| Stemke-Hale K | 2008 | Spain, Netherlands and USA | HB | H | 80(34.5) | 23 known mutations | MS | NR | OS, RFS |
| Beelen K | 2014 | Netherlands | HB | Control arm | 28(25.2) | exon 9 and 20 (HS) | SM | 93.6 | RFS |
| Ellis MJ | 2010 | Multicentre | HB | H | 45(29.4) | exon 9 and 20 | DS | NR | RFS* |
| Maruyama N | 2007 | Japanese | HB | H, C | 54(28.7) | exon 1, 2, 4, 7, 9, 13, 18, and 20 | DS | 64 (38–88) | RFS |
C, Chemotherapy; T: Trastuzumab; H, Hormonal therapy; RT, Radiothrapy; HRM, high resolution melting analysis.
*only exon 20 mutations were analyzed.